In a clinical trial, pure genistein supplementation (54 mg/day, P.O for one year) improved both cardiac function and left atrial remodeling in postmenopausal women with metabolic syndrome [138]
Ma, X., Zhu, T
Research findings reveal substantially elevated gastrointestinal risks demonstrating: Pancreatitis Risk : Patients using GLP-1 agonists showed a 9.09-fold increased risk (adjusted hazard ratio) for developing pancreatitis compared to those using alternative weight loss medications Gastroparesis Development : The study revealed a 3.67-fold increased risk for gastroparesis, often occurring secondary to pancreatic inflammation Bowel Obstruction : A 4.22-fold increased risk for intestinal blockages was documented, frequently accompanying severe gastroparesis cases FDA Adverse Event Reports : Analysis of the FDAs FAERS database through 2024 shows over 900 reported cases of pancreatitis specifically linked to semaglutide use Post-Marketing Surveillance : Real-world data from 2023-2024 indicates that serious gastrointestinal events occur more frequently than initially reported in clinical trials When pancreatitis develops, the inflamed pancreas releases numerous enzymes, toxic substances, and vasoactive compounds including inflammatory cytokines that can damage the autonomic nervous system controlling gastric function
Though not FDA-approved for weight loss, Mounjaro has been shown to help with weight loss in people with obesity
Monitoring and Managing Side Effects For weight loss, your body may tolerate well, though some people may experience side effects, especially during the introductory phase or after a dosage increase
